MOH & MHA clarify position on cannabinoid pharmaceuticals

Drugs containing cannabinoids – chemical compounds found in the cannabis plant- must undergo rigorous scientific review by the Health Sciences Authority (HSA) before being registered and supplied here.

In a joint statement yesterday to clarify the Government’s position on these pharmaceutical products, the Ministry of Home Affairs (MHA) and Ministry of Health (MOH) said there are strict frameworks in place for the supply, prescription and dispensation of such drugs. They must be prescribed for the condition registered with the HSA and by a Singapore doctor.

Manufacturers of cannabinoid pharmaceuticals have to substantiate the safety, quality and efficacy of their products, based more at


Leave a Reply